Interactions : אינטראקציות

4.5   Interaction with other medicinal products and other forms of interaction
Potentiation of effects including increased risk of adverse effects:
- Anticoagulants / thrombolytics: When taken before thrombolytic treatment, acetylsalicylic acid can increase the risk of bleeding. It is therefore important to be alert to signs of external or internal bleeding in patients who are scheduled to undergo thrombolytic treatment.
- Platelet aggregation inhibitors, e.g. ticlopidine, clopidogrel: Increased risk of bleeding.
- Other non-steroidal analgesic/anti-inflammatory drugs (at doses of 3 g acetylsalicylic acid per day and above): Increased risk of gastrointestinal ulcers and bleeding.
- Systemic glucocorticoids (except hydrocortisone as replacement therapy in Addison's disease): Increased risk of gastrointestinal side effects.
- Alcohol: Increased risk of gastrointestinal ulcers and bleeding.
- Digoxin: Increased plasma concentration.
- Antidiabetics: blood sugar levels may fall.
- Methotrexate: Reduced excretion and displacement from plasma protein binding sites by salicylates (see section 4.3).
- Valproic acid: Displacement from plasma protein binding sites by salicylates can occur.
- Selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding due to synergistic effects.

Attenuation of effects:
- Diuretics (at doses of 3 g acetylsalicylic acid per day and above).
- ACE inhibitors (at doses of 3 g acetylsalicylic acid per day and above).
- Uricosuric agents (e.g. probenecid, benzbromarone).